At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 13 Jan 2004 No development reported - Preclinical for Somatotropin deficiency in USA (PO)
- 29 Nov 2000 Profile reviewed but no significant changes made
- 05 Aug 1999 Preclinical development for Somatotropin deficiency in USA (PO)